Sugi Predict

Sugi Predict / Compounds / SCHEMBL429907

SCHEMBL429907

SCHEMBL429907

CN(N)C(=S)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.67
▸ MAPT P10636 2/20 0.67
▸ HSP90AA1 P07900 2/20 0.64
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ HPGD P15428 2/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ HSP90AB1 P08238 1/20 0.48
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ FAAH O00519 1/20 0.39
▸ PHGDH O43175 1/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ ATM Q13315 1/20 0.38
▸ METTL3 Q86U44 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608389 0.80 ALDH1A1 (1.00) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL9133892 0.80 ALDH1A1 (0.58) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL8949752 0.78 HSP90AA1 (1.00) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL1642103 0.77 ALDH1A1 (0.40) ALDH1A1MAPTHSP90AA1KMT2AHPGD
SCHEMBL15402110 0.76 ALDH1A1 (0.67) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL8949737 0.76 HSP90AA1 (0.95) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL9199685 0.76 HSP90AA1 (0.95) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL9507508 0.76 ALDH1A1 (0.54) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL13292788 0.76 PARP1 (0.48) ALDH1A1MAPTHSP90AA1MEN1KMT2A
SCHEMBL1643901 0.76 ALDH1A1 (0.50) ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435843-B2 Synthesis of taxol enhancers SYNTA PHARMACEUTICALS CORP. (US) 2008-10-14 — — US claimed
US-20150344420-A1 PACLITAXEL ENHANCER COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2015-12-03 — — US disclosed
US-20150344420-A1 PACLITAXEL ENHANCER COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2015-12-03 — — US disclosed
US-20150344420-A1 PACLITAXEL ENHANCER COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2015-12-03 — — US disclosed
US-9156783-B2 Compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-10-13 — — US disclosed
US-9156783-B2 Compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-10-13 — — US disclosed
US-9156783-B2 Compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-10-13 — — US disclosed
US-9107955-B2 Paclitaxel enhancer compounds SYNTA PHARMACEUTICALS CORP. (US) 2015-08-18 — — US disclosed
US-9107955-B2 Paclitaxel enhancer compounds SYNTA PHARMACEUTICALS CORP. (US) 2015-08-18 — — US disclosed
US-9107955-B2 Paclitaxel enhancer compounds SYNTA PHARMACEUTICALS CORP. (US) 2015-08-18 — — US disclosed
US-20040225016-A1 administering bis[thio-hydrazide amide] Compounds for treating multi-drug resistant cancer SYNTA PHARMACEUTICALS CORPORATION 2004-11-11 — — US disclosed
US-6800660-B2 BIS(THIO-HYDRAZIDE AMIDE) COMPOUNDS; ANTICANCER AGENTS SYNTA PHARMACEUTICALS CORP. 2004-10-05 — — US disclosed
WO-2004064826-A1 BIS (THIO-HYDRAZIDE AMIDE) COMPOUNDS FOR TREATING MULTI-DRUG RESISTANT CANCER SYNTA PHARMACEUTICALS CORP. (US) 2004-08-05 — — WO disclosed
EP-1406869-A1 TAXOL ENHANCER COMPOUNDS Synta Pharmaceuticals Corporation (US) 2004-04-14 — — EP disclosed
EP-1406868-A1 SYNTHESIS OF TAXOL ENHANCERS Synta Pharmaceuticals Corporation (US) 2004-04-14 — — EP disclosed
US-20030195258-A1 Taxol enhancer compounds SYNTA PHARMACEUTICALS CORP. (US) 2003-10-16 — — US disclosed
US-20030119914-A1 Taxol enhancer compounds SHIONOGI BIORESEARCH CORP. 2003-06-26 — — US disclosed
US-20030069225-A1 Synthesis of taxol enhancers SHIONOGI BIORESEARCH CORP. 2003-04-10 — — US disclosed
WO-2003006430-A1 TAXOL ENHANCER COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2003-01-23 — — WO disclosed
WO-2003006429-A1 SYNTHESIS OF TAXOL ENHANCERS SYNTA PHARMACEUTICALS CORP. (US) 2003-01-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225016-A1 administering bis[thio-hydrazide amide] Compounds for treating multi-drug resistant cancer CBR1, ABCC1, CBR3 ALDH1A1 107/4885MAPT 4130/4885HSP90AA1 2230/4885
US-20030195258-A1 Taxol enhancer compounds ABCB1, ABCB11, CCNY ALDH1A1 729/4885MAPT 1980/4885HSP90AA1 3174/4885
US-20030069225-A1 Synthesis of taxol enhancers TOP2B, TUBB1, TUBA1B ALDH1A1 626/4885MAPT 811/4885HSP90AA1 651/4885
US-20150344420-A1 PACLITAXEL ENHANCER COMPOUNDS FOXM1, ABCC8, ABCB1 ALDH1A1 1765/4885MAPT 2817/4885HSP90AA1 3691/4885
US-20030119914-A1 Taxol enhancer compounds ABCB1, ABCB11, CENPE ALDH1A1 783/4885MAPT 1925/4885HSP90AA1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.